Related Experiment Video
Updated: May 7, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Screening for and management of elevated Lp(a)
Michael B Boffa1, Marlys L Koschinsky
1Department of Chemistry & Biochemistry, University of Windsor, 401 Sunset Avenue, Windsor, Ontario, Canada, mboffa@uwindsor.ca.
Insights
Lipoprotein(a) (Lp(a)) is a causal factor for cardiovascular disease. Research is exploring optimal patient groups for Lp(a) testing, management strategies, and risk reduction efficacy.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Epidemiology
Background:
- Lipoprotein(a) (Lp(a)) is a recognized cardiovascular risk factor.
- Genetic studies confirm Lp(a) as causal for atherothrombotic disease, not just a marker.
- Clinical utilization of Lp(a) for risk prediction is a recent development.
Purpose of the Study:
- To review recent advancements in Lp(a) research.
- To explore the clinical integration of Lp(a) in risk assessment and management.
- To address outstanding questions regarding Lp(a) and cardiovascular risk.
Main Methods:
- Review of genetic studies.
- Summary of basic laboratory research findings.
- Analysis of epidemiological data.
- Focus on clinical practice implications.
Main Results:
- Lp(a) is established as a causal factor in atherothrombotic disease.
- Ongoing research addresses optimal patient selection for Lp(a) testing.
- The effectiveness of Lp(a) reduction on clinical outcomes is under investigation.
Conclusions:
- Further research is needed to define the precise role of Lp(a) in clinical practice.
- Understanding the molecular mechanisms of Lp(a) risk is crucial.
- Effective management strategies for elevated Lp(a) are a key area of focus.
Abstract:
While lipoprotein(a) (Lp(a)) has long been an intriguing subject for basic researchers and clinicians alike, it is only recently that this unique cardiovascular risk factor has begun to be broadly utilized as part of risk prediction. This has dovetailed with the recognition, from genetic studies, that Lp(a) is indeed causal for atherothrombotic disease rather than being merely a marker. Yet, significant questions remain the subject of ongoing study including: what patients groups benefit the most from determination of plasma Lp(a) concentrations; how can elevated plasma Lp(a) concentrations be most effectively managed; does reduction in plasma Lp(a) concentrations reduce risk for atherothrombotic events; and what is the molecular mechanism or mechanisms underlying the risk attributed to elevated Lp(a)? This review summarizes recent progress in genetic studies, basic laboratory research, and epidemiology with a focus on how Lp(a) might be incorporated into clinical practice.
Related Concept Videos
Atherosclerosis IV: Nursing Management
Atherosclerosis III: Management
Mitral Valve Prolapse II: Assessment and Management
Aneurysm III: Interprofessional Care
Mitral Valve Prolapse III: Nursing Management
Aortic Regurgitation III: Medical Management
